University of Illinois, Cancer Center
Welcome,         Profile    Billing    Logout  
 2 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Peace, David
NCT04431635: Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Terminated
1
6
US
Copanlisib, Nivolumab, Rituximab
University of Michigan Rogel Cancer Center, Bayer, Bristol-Myers Squibb, University of Michigan, Big Ten Cancer Research Consortium
Indolent Lymphoma
11/23
11/23
Toh, Roxana
BTCRC-BRE19-409, NCT04762979: Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Recruiting
2
44
US
Alpelisib, Fulvestrant, Aromatase inhibitor
Marina N Sharifi, Novartis, University of Wisconsin, Madison
Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer
09/25
01/26
NCT04070768: Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

Active, not recruiting
1
18
US
Gemtuzumab Ozogamicin, GO, Venetoclax
John Quigley, Pfizer, AbbVie
Acute Myeloid Leukemia
10/23
10/24

Download Options